Prof. Zhijun Yang (Ph.D.) is a professor at the School of Chinese Medicine at Hong Kong Baptist University (SCM, HKBU). Before his Professor, Pro. Yang served for 18 years as an assistant professor and an associate professor of the Teaching Division of the SCM, HKBU, where he earned a reputation as an expert in the pharmaceutical formulation in Chinese Materia Medica and Drug Delivery System that shaped the pharmaceutical laboratory based on the principles of pharmaceutical science and the traditional Chinese medicine.

Prof. Yang graduated from Shenyang Pharmaceutical University in 1986 and received a bachelor’s degree of science (BSc, in pharmacy), after that he became an assistant teacher and then a lecturer at China Pharmaceutical University. During this period, he studied the basic theories of Traditional Chinese Medicine at Nanjing University of Traditional Chinese Medicine and conducted pharmaceutical research at Gifu Pharmaceutical University in Japan as a visiting scholar. Supporting with Grants-in-Aid for Scientific Research of the Ministry of Education, Science, Sports and Culture of Japan, from October 1993, he researched pharmaceutical formulations as a visiting scholar and then a doctoral candidate at Chiba University in Japan and obtained a Ph.D. in Pharmaceutical Science in 1997. Subsequently, Prof. Yang assumed the duty of a researcher at Taiyo Pharmaceutical Industry Ltd. (July 14, 2011, Teva Pharmaceuticals purchased its majority stake, and then the company turned into Teva Takeda Yakuhin Ltd.) in Japan. In 2000, Prof. Yang carried out his postdoctoral research at the University of British Columbia, Canada. One year later, he served in Northern Lipids Inc. (June 21st, 2016 turned as Evonik acquires Transferra Nanosciences Inc.) in Canada as a scientist to develop Liposome Formulation.

Over these years, Prof. Yang has been engaged in the development and research of pharmaceutics for chemical and natural active pharmaceutical ingredients (API). He has attained remarkable results both in publications and pharmacy market products. Currently, Prof. Yang is focusing on the front-line research of pharmaceutics to develop the formulation of API by combining the theories of Traditional Chinese Medicines (TCM) and Drug Delivery Systems (DDS). The following concise list shows the concrete achievements.

1. Prof. Yang has lectured or tutored subjects, 1) Biopharmaceutics, 2) Pharmaceutics in Chinese Medicine, 3) The Pharmaceutics of Chinese Materia Medica Laboratory, 4) Advanced Pharmaceutics in Chinese Medicine, 5) Translational Medine and Drug Discovery, 6) Laboratory Practice in Chinese Medicines, and so on. The span of the subjects has shown Prof. Yang possesses professional knowledge, vision, and intelligence.
2. Prof. Yang has designed the syllabi, teaching materials, and assessment methods. Prof. Yang in HKBU is the pathfinder of the related courses such as Pharmaceutics in Chinese Materia Medica etc. Prof. Yang established a pharmaceutical laboratory that fulfills all the requirements of Biopharmaceutics and the Pharmaceutics of Chinese Medicine both in teaching and research of pharmaceutical developments.
3. Prof. Yang has been an instructor of the postdoctoral fellows, the doctoral candidates at HKBU.
4. Prof. Yang has published over 80 papers in the preparation of pharmaceutical science for HKBU. Prof. Yang’s papers are not only enough in quantity but also incontestable high qualities published in the top journals of science, such as Biomaterials, Nature Medicine, Nature Communications, J. Mater. Chem. B, International Journal of Nanomedicine, Drug Delivery, etc.
5. Prof. Yang had worked in the industry for over five years. And for HKBU, he has applied and been authorized over 10 patents for many potential novelty pharmaceutical products. In this era, most of the patents for novelty pharmaceutical products are devised by pharmaceutical companies with a global comparative strong science-based foundation.
6. Prof. Yang has awarded research grants to over ten million Hong Kong dollars for HKBU for pharmaceutical developments.
7. Prof. Yang serves as a member for Member of the Pharmaceutical Society of Japan and many committees of HKBU.

Since joining SCM, HKBU on June 16, 2003, Prof. Yang has made and is continuously making contributions both to the SCM, HKBU, and the academic of Pharmaceutics in Traditional Chinese Medicine.

Developing less-invasive or non-invasive routes including subcutaneous, transdermal, oral, inhalation, nasal, and buccal routes, and technologies to deliver therapeutic agents, intelligent systems/biomolecular devices for the systemic and intracerebral delivery of API extracted from TCM and biologics; searching the factors to the performance of pressurized metered dose inhalers, dry powdered inhalers, nebulizers, and nasal sprays; and, investigating the structure-function relationships of proteins, carbohydrates, and nucleic acids targeting cancer and other diseases.